CI

At a glance

ClinicalIndex Comparison Record
N/ACompleted· 20 enrolled
Drug / intervention
Phenylephrine 2.5%drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02965924
NCT02965924N/ACompleted

Effect of Topical Phenylephrine 2.5% on Episcleral Venous Pressure in Normal Human Eyes

Mayo Clinic·interventional·Posted Nov 17, 2016·Updated Oct 23, 2019

In Brief

A clinical study evaluating Phenylephrine 2.5% for Assess Phenylephrine on EVP and IOP. Completed, enrolled 20 participants across 1 site.

Detailed Summary

Phenylephrine hydrochloride ophthalmic solution is an alpha-1 adrenergic receptor agonist commonly used topically for dilation prior to ocular fundus examination. In the eye, phenylephrine acts locally as a potent vasoconstrictor and mydriatic by constricting ophthalmic blood vessels and the radial dilator muscle of the iris. Episcleral venous pressure (EVP) is a determinant of intraocular pressure (IOP) and can be measured non-invasively by venomanometry. Since phenylephrine is a vasoconstrictor, it may affect episcleral venous tone, but the effect on EVP is unknown. Understanding the physiology of episcleral veins helps us in better understanding of pathophysiology of glaucoma.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesUnited States
Collaborators--

Timeline

N/ACompletedFinished
2017201820192020202120222023202420252026
First PostedNov 17, 2016
Enrollment StartOct 1, 2016
Primary CompletionOct 1, 2018
TodayJul 2, 2026
Enrollment to primary: 2 yearsPosted 9.6 years ago

Interventions

Phenylephrine 2.5%drug

Instilling phenylephrine 2.5% eye drop